Recce Pharmaceuticals Ltd
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| RCE.AX | FBIO | BSLN.SW | ANTX | IBO | NIKI | |
|---|---|---|---|---|---|---|
| Market cap | 100.93M | 65.70M | 915.92M | 160.38M | 35.42M | 5.27M |
| P/E (TTM) | — | 0.7 | 18.6 | — | 0.4 | — |
| Forward P/E | 17.4 | -1.1 | 14.4 | -5.3 | — | — |
| Price/book | -5.7 | 0.4 | 5.6 | 2.0 | 3.3 | 0.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −19.28% | −21.77% | +60.26% | +279.46% | −40.30% | −87.62% |
| Today | −1.49% | +1.55% | +0.27% | +1.67% | +1.99% | −3.98% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All RCE.AX news ›Recce Pharmaceuticals and Arrotex Pharmaceuticals announce Exclusive License and Commercialisation Agreement
Under the terms of the agreement, Recce will remain the exclusive manufacturer and supplier and receive a significant profit share from product sales. Arrotex will obtain exclusive commercialisation rights for R327G for the treatment of…
Small Cap Wrap: Anteris Technologies secures German clearance; Recce Pharmaceuticals advances Phase 3 diabetic foot infection trial and more...
Australia’s Fair Work Commission has introduced new rules requiring people to disclose when they use generative artificial intelligence to prepare workplace cases, as AI-generated applications contribute to a surge in the tribunal’s…
Recce Pharmaceuticals advances Phase 3 diabetic foot infection trial to independent data review
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has reached a key milestone in its pivotal Phase 3 diabetic foot infection trial, with an independent Data Monitoring Committee (DMC) set to review unblinded efficacy and safety data after a…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- proactiveinvestors.com2
- retailpharmacymagazine.com.au1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.